Sequencing multiple myeloma therapies with and after antibody therapies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sequencing multiple myeloma therapies with and after antibody therapies
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2020, Issue 1, Pages 248-258
Publisher
American Society of Hematology
Online
2020-12-05
DOI
10.1182/hematology.2020000109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab
- (2020) Kristine A. Frerichs et al. CLINICAL CANCER RESEARCH
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
- (2020) Nizar J. Bahlis et al. LEUKEMIA
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
- (2020) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
- (2020) Jesus G. Berdeja et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
- (2019) Philippe Moreau et al. Blood Cancer Journal
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2019) Ajai Chari et al. BLOOD
- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients
- (2019) Ajay K. Nooka et al. CANCER
- Understanding mortality in multiple myeloma: findings of a European retrospective chart review
- (2019) Mohamad Mohty et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
- (2019) Maria-Victoria Mateos et al. HAEMATOLOGICA
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) David S. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
- (2018) Amrita Krishnan et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies
- (2018) Praful Ravi et al. Blood Cancer Journal
- Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
- (2018) Rimke Oostvogels et al. BRITISH JOURNAL OF HAEMATOLOGY
- Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
- (2018) Meletios A. Dimopoulos et al. CANCER
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- (2018) Meletios A. Dimopoulos et al. HAEMATOLOGICA
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
- (2018) Laurens E. Franssen et al. Oncotarget
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
- (2018) Saad Z. Usmani et al. Blood Cancer Journal
- Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach
- (2017) Marc-Andrea Baertsch et al. HEMATOLOGICAL ONCOLOGY
- Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma
- (2017) Chrissy H.Y. van Beurden-Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
- (2017) S K Kumar et al. LEUKEMIA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
- (2016) Rachid C. Baz et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Multiple myeloma: patient outcomes in real-world practice
- (2016) Kwee Yong et al. BRITISH JOURNAL OF HAEMATOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
- (2016) Gordon Cook et al. Lancet Haematology
- Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
- (2016) Jesús F San-Miguel et al. Lancet Haematology
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started